Biogen Idec: Tecfidera not cause of patient's death

Share this article:

Biogen Idec said the death of a patient in July was not caused by its MS drug Tecfidera, reported the Wall Street Journal, which says the patient's physician came to this conclusion.

The patient had taken Tecfidera but stopped her regimen two-and-a-half weeks before she died, due to side effects including vomiting and diarrhea. Biogen Idec told Pharmalot at the time that this was important to note because the death was not “GI related.”

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.